Organization · Venture Capital
Ninteen Twenty-One
Nineteen Twenty-One is a Vienna-based venture capital fund focused on early-stage investments in companies addressing type 1 diabetes and its related health issues. The fund aims to support technology-enabled and biology-driven solutions in the healthcare sector.
Overview
What Ninteen Twenty-One does
What Ninteen Twenty-One is
Nineteen Twenty-One is a Vienna-based venture capital fund focused on early-stage investments in companies addressing type 1 diabetes and its related health issues. The fund aims to support technology-enabled and biology-driven solutions in the healthcare sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2025
- Approximate age
- About 1 year
- Structured capabilities
- Funder
- Last reviewed
- March 31, 2026
Official channels
Find Ninteen Twenty-One elsewhere
Open the official website or a supported primary organization account.
Capability profile
Ninteen Twenty-One as a funder
Investment thesis
Nineteen Twenty-One focuses on investing in early-stage companies developing solutions for type 1 diabetes and its associated health issues. The organization aims to support mission-driven teams with technology-enabled or biology-driven innovations.
Focus narrative
Nineteen Twenty-One invests primarily in early-stage companies that are tackling type 1 diabetes and its associated health complications. The fund aims to provide financial support ranging from €200,000 to €1.5 million, with a target fund size of €10 million. By emphasizing collaboration with mission-driven teams, Nineteen Twenty-One seeks to foster the development of technology-enabled and biology-driven solutions that can significantly improve the lives of those affected by T1D.
Value beyond capital
Nineteen Twenty-One adds value to its portfolio companies through its deep understanding of the type 1 diabetes ecosystem, leveraging the founder's personal experience with T1D and a strong advisory network of experts in the field. The fund's focus on early-stage investments allows it to provide not only capital but also strategic guidance and connections within the diabetes community.
Terms and economics
- Typical check
- $200,000–$1,500,000
- Sweet spot
- $500,000
Focus and fit
- Stages
- Friends and Family · Angel · Pre-seed · Seed · Series A
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
- Recorded notable exits
- mySugr
Portfolio context
Nineteen Twenty-One's portfolio includes innovative companies such as OneTwenty, Lapsi, Syntactiq, Ona Labs, T1D Scout, and Next Cell Pharma AB, all of which are focused on advancing solutions for type 1 diabetes and its comorbidities.
Common questions
What to know about Ninteen Twenty-One
Upseed classifies Ninteen Twenty-One under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 31, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.